A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine

Phase 1

Completed

• Conditions: Neoplasms

• Registration Number: NCT00390676
• Lead Sponsor: Adherex Technologies, Inc.

Brief Summary

N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and docetaxel or ADH-1 and capecitabine in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-10-18
• Study First Submitted QC: 2006-10-19
• Study First Posted: 2006-10-20
• Study Start: 2006-11
• Study Completion: 2009-11
• Status Verified: 2010-12
• Last Update Submitted: 2010-12-27
• Last Update Posted: 2010-12-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (10)

Virginia Oncology Associates; 🇺🇸 Norfolk, Virginia, United States

New York Oncology Hematology P.C.; 🇺🇸 Albany, New York, United States

Texas Oncology, PA; 🇺🇸 Dallas, Texas, United States

Central Indiana Cancer Centers; 🇺🇸 Indianapolis, Indiana, United States

Cancer Centers of Florida; 🇺🇸 Ocoee, Florida, United States

Northwest Cancer Specialists - Vancouver Cancer Center; 🇺🇸 Vancouver, Washington, United States

Tyler Cancer Center; 🇺🇸 Tyler, Texas, United States

Dayton Oncology & Hematology, P.A; 🇺🇸 Kettering, Ohio, United States

Cancer Centers of the Carolinas; 🇺🇸 Greenville, South Carolina, United States

Rocky Mountain Cancer Centers; 🇺🇸 Denver, Colorado, United States